Navigation Links
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/25/2008

ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases,
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces 2008 Corporate and Clinical Program Priorities
2. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
3. EntreMed to Present at BIO CEO and Investor Conference
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. EntreMed Appoints Senior Vice President of Research and Development
7. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
8. Osteotech to Present at the Sidoti Conference in New York
9. BioMS Medical to present at BioCentury Conference
10. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Cambridge Semantics , ... by Semantic Web technology, and Informa , ... services for the academic and scientific, professional and ... solution ‘Smart Data Lake for Clinical Trial and ... 2015 Bio-IT ‘Best of Show’ Award. , ...
(Date:4/16/2015)... April 16, 2015 Regis Technologies looks ... Association for Cancer Research (AACR) annual meeting. Regis will ... Center, starting Saturday, April 18, in Philadelphia and running ... to title of the oldest and largest organization focused ... and grants, and partners with survivors to promote awareness ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ... Securities Exchange: PBT.U), is pleased to announce that the ... on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon , ... an update on the key programs at its subsidiaries, ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... Other important parameters for optimizing electroporation., , , , , , , ... , Pulse length , , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , Influence ...
... , , , , ... , to degradation than DNA. Unlike Deoxyribonucleases (DNases), ... can therefore easily be inactivated with chelating , ... requirements and advantage of the 2 hydroxyl groups adjacent to ...
... How can Brinkmann TM Help ? , , , , , ... , , ... laboratory technique that is performed everyday, for a good portion , ... Due to the nature of the tests being conducted, only short breaks , ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Decontamination and inhibition of ribonucleases 2Decontamination and inhibition of ribonucleases 3Decontamination and inhibition of ribonucleases 4Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 2Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 3Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 4
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... are significantly more open to the idea of "designing" babies ... psychologists at the University of East Anglia. , The findings ... Festival of Science on Setpember 5. , Dr. Hampton and ... Studies examined what different groups of people in the UK ...
... that influences several aspects of nicotine-induced behaviors in the ... Drug Abuse, was presented today at the American College ... PhD, associate professor of psychiatry and her colleagues at ... a molecule called CREB in a brain area called ...
... In a finding that broadens our understanding of ... risk when crossing roads and draw on an ... primates--of protective "socio-spatial" organization that produces flexible, adaptive, ... facing risk. The research is reported by Kimberley ...
Cached Biology News:Designer babies - what would you do for a 'healthy' baby? 2New research identifies gene important for nicotine's effects on the brain 2Road-crossing in chimpanzees: A risky business 2
Performance, mycoplasma, virus, and endotoxin tested...
... Gel Loading Buffer is ... and tracking of DNA ... native polyacrylamide gels. This ... density sucrose which allows ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
ready-to-use solution...
Biology Products: